Latest Dana-Farber Cancer Institute Stories
First in Cancer, Cardiology & Heart Surgery, Nephrology, Neurology & Neurosurgery, Orthopedics and Urology BOSTON, May 17, 2011 /PRNewswire-USNewswire/ -- Children's Hospital Boston ranks first in more specialties than any other children's hospital in the nation according to the 2011-12 edition of Best Children's Hospitals by U.S.
PHILADELPHIA, May 9, 2011 /PRNewswire-USNewswire/ -- Children with life-threatening illnesses receive hospital-based palliative care services for an average of more than a year, far longer than adults who require similar end-of-life support, according to a new study from the Pediatric Palliative Care Research Network and PolicyLab at The Children's Hospital of Philadelphia. The majority of children were treated for genetic, congenital, neuromuscular, breathing and stomach illnesses, much...
Like brainy bookworms unprepared for the rough and tumble of post-graduation life, white blood cells trained by scientists to attack tumors tend to fade away quickly when injected into cancer patients.
A leukemia drug may be used as a new target therapy for some lung cancer patients.
COLUMBUS, Ga., April 4, 2011 /PRNewswire/ -- Aflac, the company that helps employers enhance benefits offerings to employees, today announced it will donate a total of $1,060,000 to the American Association for Cancer Research (AACR) to help defray the costs facing cancer researchers.
Scientists have achieved one of the oldest and most rarely achieved goals of cancer researchâ€”they have found a way to â€œdistractâ€ cancer cells from their normal activities and make them act like normal cells.
A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising.
Innovative international research consortium's first study opens SAN FRANCISCO, March 28, 2011 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy") today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma.
BOSTON, March 24, 2011 /PRNewswire/ -- John Legere, CEO of Global Crossing, is nearing the finish line of his goal to raise $1 million for cancer research at Dana-Farber Cancer Institute.
- A hairdresser.